Can leukemic cells infiltrate into the soft tissue of the leg in a patient with leukemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 24, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Leukemic Cells Infiltrate Soft Tissue of the Leg?

Yes, leukemic cells can definitively infiltrate into the soft tissue of the leg, though this represents an uncommon extramedullary manifestation of leukemia that requires systemic chemotherapy rather than local treatment alone.

Extramedullary Leukemic Infiltration: Overview

Leukemic cells can infiltrate virtually any extramedullary site, including soft tissues of the extremities, though this occurs less frequently than involvement of lymph nodes, skin, and bones 1, 2. When this occurs, it represents a serious manifestation requiring aggressive systemic therapy 3.

Myeloid Sarcoma (Granulocytic Sarcoma)

Myeloid sarcoma is the most well-characterized form of soft tissue leukemic infiltration, occurring in 5-7% of patients with acute myeloid leukemia (AML). 2

  • These are tumor masses consisting of myeloid blasts that efface tissue architecture at anatomical sites other than bone marrow 1
  • Most commonly involve skin, lymph nodes, gastrointestinal tract, bone, and soft tissue 1
  • Require systemic AML-directed chemotherapy, not just local treatment, as emphasized by the American Society of Hematology 3
  • Distinguished from frank AML by having less than 20% bone marrow blasts 3

Intramuscular Leukemic Relapse (ILR)

Intramuscular involvement, while very unusual, is a documented phenomenon with specific clinical and radiologic features. 4

Clinical Presentation

  • Manifests as focal pain, swelling, and muscle weakness in the affected area 4
  • Most commonly involves the extremities (44% of cases) 4
  • Acute myeloid leukemia is the most common underlying diagnosis 4

Radiologic Features

  • Diffuse muscle infiltration is the most common imaging pattern 4
  • On MRI: hypointense to isointense on T1-weighted images, hyperintense on T2-weighted images 4
  • Demonstrates homogeneous enhancement on post-contrast CT/MRI 4
  • CT and MRI are both effective for detection and characterization 4

Other Leukemia Types and Soft Tissue Involvement

Plasma cell leukemia (PCL) can also involve soft tissues, though this is exceedingly rare. 5

  • Extramedullary involvement including soft tissue is documented but extremely uncommon 5
  • One case report describes subcutaneous nodules in pelvic and gluteal regions with PCL 5
  • PCL has high frequency of extramedullary involvement overall, making imaging evaluation with MRI or PET/CT important 1

Hairy cell leukemia typically infiltrates bone marrow and spleen but may extend to other sites. 1

  • Leukemic cells may be found in liver and lymph nodes 1
  • Peripheral lymphadenopathy is uncommon 1

Diagnostic Approach

When to Suspect Soft Tissue Leukemic Infiltration

Consider this diagnosis in any patient with known leukemia who develops:

  • New focal pain, swelling, or mass in an extremity 4
  • Muscle weakness localized to a specific region 4
  • Palpable soft tissue masses 6

Diagnostic Workup

Tissue biopsy is essential for definitive diagnosis, as leukemic infiltration can mimic other conditions. 6

  1. Imaging studies:

    • MRI is preferred for soft tissue characterization 4
    • CT can identify masses and assess enhancement patterns 4
    • Look for diffuse muscle infiltration or discrete masses 4
  2. Biopsy with proper specimen handling:

    • Fresh specimens should be obtained when possible 6
    • Touch imprints should be performed 6
    • Immunohistochemistry is crucial for lineage determination 1, 3
    • Flow cytometry helps characterize blast phenotype 3
  3. Systemic evaluation:

    • Bone marrow examination to assess marrow involvement 3
    • Complete blood count with differential 7
    • Imaging to identify other extramedullary sites 1

Critical Pitfalls to Avoid

Extramedullary leukemia presenting as soft tissue masses can be misdiagnosed as lymphoma or other solid tumors, especially when clinical history is not available. 3, 6

  • Systematic specimen handling and proper triaging are keys to reducing diagnostic error 6
  • Immunochemical methods are essential to demonstrate leukemic cells in tissue 8
  • Do not treat with local therapy alone—systemic chemotherapy is required 3

Treatment Implications

Any soft tissue leukemic infiltration requires systemic chemotherapy directed at the underlying leukemia. 3

  • Local treatment alone is inadequate 3
  • Decreasing joint or soft tissue pain is often the first sign of clinical response to chemotherapy 8
  • The presence of extramedullary disease may indicate more aggressive disease requiring intensified therapy 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Leukemic Involvement in the Thorax.

Radiographics : a review publication of the Radiological Society of North America, Inc, 2019

Guideline

Extramedullary Hematopoiesis in Myeloid Sarcoma and Other Hematologic Disorders

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Leukemia presenting as solid tumors: report of four pediatric cases and review of the literature.

Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society, 2008

Guideline

Blast Crisis in Leukemia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Leukemic arthritis.

Seminars in arthritis and rheumatism, 1994

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.